SCHEMBL3387935

SCHEMBL3387935

CN(CCCNC(=O)C1CCC1)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.44
CA14 Q9ULX7 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
FPR3 P25089 1/20 0.40
FPR2 P25090 1/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
METAP2 P50579 1/20 0.37
ITGB3 P05106 2/20 0.36
ITGA2B P08514 2/20 0.36
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36
GNAI1 P63096 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22123780 0.88 GNAI3 (0.51) NAAACA14SMN1; SMN2HSD17B10FPR3
SCHEMBL22123103 0.80 GNAI3 (0.47) CA14SMN1; SMN2HSD17B10FPR3FPR2
SCHEMBL3389480 0.79 TDP1 (0.53) NAAASMN1; SMN2HSD17B10FPR3FPR2
SCHEMBL18282365 0.78 TDP1 (0.50) CA14ALDH1A1TDP1BTKKMT2A
SCHEMBL31040440 0.78 CA14 (0.50) CA14FPR3FPR2TDP1METAP2
SCHEMBL13622518 0.78 TDP1 (0.60) CA14TDP1KMT2A
SCHEMBL28617700 0.77 HSD17B10 (0.47) SMN1; SMN2HSD17B10FPR3FPR2ALDH1A1
SCHEMBL18651728 0.77 CA14 (0.49) CA14FPR3FPR2TDP1METAP2
SCHEMBL13189519 0.75 NAAA (0.53) NAAASMN1; SMN2HSD17B10LMNAALDH1A1
SCHEMBL20142566 0.75 HPGD (0.50) HSD17B10LMNAALDH1A1KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 NAAA 4405/4885CA14 1619/4885SMN1; SMN2 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.